Oligos explainer: A new frontier in precision medicine

Oligonucleotide therapies are rapidly emerging as a powerful force in modern medicine poised to transform how we address a spectrum of diseases. Yet knowledge of the industrial opportunities of these remarkable molecules often called ‘oligos’ that offer precise gene targeting capabilities opening doors to treatments once considered beyond reach remains limited beyond our sector.

In this emerging industrial space solving manufacturing challenges is key to the successful delivery of new therapies. The UK is well placed to capture the global economic value from being in the vanguard of this new industry and has wisely invested public money to support this effort.

This report aims to explain the science, the history, the opportunity and manufacturing challenges of oligos to the non-expert audience. It introduces some of the key UK players who are at the forefront of this exciting field and explains how and why we can establish ourselves as a global industrial leader in this transformative field.

Our aspiration is that this report will serve as a catalyst, amplifying awareness of the immense potential of oligonucleotide therapies and inspiring increased investment from companies and organisations alike. By forging strong partnerships and fostering collaboration, we can solidify the UK’s position as a premier destination for oligonucleotide research, development and manufacture.

The BIA is dedicated to maximising the impact of oligonucleotides through:

• Promoting the UK: Showcasing our nation’s strengths in bioscience, talent, research, and regulation. 
• Advocacy: Championing favourable policies, supportive taxation, and streamlined regulatory processes.
• Skills development: Supporting educational and training programs to cultivate a skilled oligonucleotide workforce.
• Fostering collaboration: Facilitating partnerships between companies and organisations to accelerate innovation.
• Raising awareness: Educating the public, government, and investors about the potential of oligonucleotide therapies.

We will continue to work tirelessly with our members and partners to ensure the UK remains at the forefront of oligonucleotide research and development, ultimately bringing life-changing treatments to patients worldwide.

We would also like to sincerely thank CPI for their invaluable input to this report and AstraZeneca, Oxford University, and the Medicines Discovery Catapult (MDC) for contributing their insightful case studies.